Heparin Sodium Reig Jofre Uk

Heparin Sodium Reig Jofre Uk is a prescription anticoagulant that contains the active ingredient heparin sodium. It is supplied as an injectable solution for intravenous, extracorporeal, or hemodialysis administration. The product is manufactured for the European market and conforms to EU pharmaceutical standards. As a high‑molecular‑weight polysaccharide, it works by enhancing antithrombin III activity to inhibit clotting factors. It is classified under ATC code B01AB01.

Heparin Sodium Reig Jofre Uk is indicated for several clinical situations where anticoagulation is required.

- Prevention of venous thromboembolism in patients undergoing surgery or prolonged immobilization. - Treatment of acute thrombotic events such as deep‑vein thrombosis or pulmonary embolism. - Anticoagulation during hemodialysis to maintain circuit patency. - Anticoagulation for extracorporeal circuits, including cardiopulmonary bypass and plasma exchange. - Bridging therapy when transitioning between oral anticoagulants and procedural interventions. - Prophylaxis of clot formation in patients receiving continuous renal replacement therapy. - Management of clotting risk in patients with mechanical heart valves during peri‑operative periods.

Side effects of Heparin Sodium Reig Jofre Uk reflect its anticoagulant activity and may range from mild laboratory changes to serious bleeding complications.

Common: - Minor bleeding such as injection‑site oozing, gum bleeding, or occasional nosebleeds. - Small bruises or elevated aPTT detected in routine laboratory monitoring, without clinical symptoms. - Transient rise in liver enzymes observed in some patients, returning to baseline after therapy ends. - Mild allergic skin reactions such as rash or itching, self‑limited.

Serious: - Major hemorrhage, including gastrointestinal or intracranial bleeding, which can be life‑threatening. - Heparin‑induced thrombocytopenia (HIT) with risk of new clot formation, requiring immediate discontinuation and alternative anticoagulation. - Spinal or epidural hematoma following neuraxial anesthesia, a rare but serious complication. - Severe anaphylactic reaction requiring emergency treatment, such as epinephrine administration.

Precautions for Heparin Sodium Reig Jofre Uk focus on patient assessment, monitoring, and awareness of conditions that increase bleeding risk.

- Assess baseline coagulation status, including aPTT and platelet count, before initiating therapy. - Adjust dose or avoid use in patients with active major bleeding or recent intracranial hemorrhage. - Monitor for signs of heparin‑induced thrombocytopenia during the first two weeks of treatment. - Use caution in individuals with a history of hypersensitivity to heparin or pork‑derived products. - Evaluate renal and hepatic function, as impairment may affect drug clearance and safety.

Drug interaction considerations for Heparin Sodium Reig Jofre Uk involve agents that affect coagulation pathways or platelet function.

Avoid: - Concurrent use with other anticoagulants such as warfarin, direct oral anticoagulants, or low‑molecular‑weight heparins, which markedly increases bleeding risk. - Combination with antiplatelet drugs (e.g., aspirin, clopidogrel) that can potentiate hemorrhagic complications. - Administration together with fibrinolytic agents (e.g., alteplase) that may cause uncontrolled bleeding.

Use with caution: - Concomitant use of non‑steroidal anti‑inflammatory drugs (NSAIDs) or corticosteroids, which may impair platelet function. - Overlap with drugs that lower platelet count, such as certain antibiotics (e.g., linezolid) or chemotherapy agents, requiring close monitoring.